Recent advances in the frontline treatment of metastatic renal cell carcinoma  

作　　者：Camillo Porta Mimma Rizzo 

机构地区：[1]Department of Biomedical Sciences and Human Oncology,University of Bari‘A.Moro’,Bari 70124,Italy [2]Division of Medical Oncology,A.O.U.Consorziale Policlinico di Bari,Bari 70124,Italy [3]Division of Translational Oncology,I.R.C.C.S.Istituti Clinici Scientifici Maugeri,Pavia 27100,Italy

出　　处：《Journal of Cancer Metastasis and Treatment》2021年第1期695-706,共12页癌症转移与治疗（英文版）

摘　　要：We aim to describe the most recent advances in the upfront treatment of metastatic renal cell carcinoma,and to provide criteria-though often subjective-which could be used for treatment selection,by means of a critical review of the results of novel trials of immune-based combinations,coupled with personal considerations and experiences.To date,5 immune-based combinations have been tested within large phase III trials;four of them yielded a significant overall survival benefit(Ipilimumab+Nivolumab,Pembrolizumab+Axitinib,Nivolumab+Cabozantinib and Pembrolizumab+Lenvatinib),while the combination of Avelumab+Axitinib,although reaching study primary endpoint,determined just a significant progression-free survival benefit.In terms of safety,the excess of adverse events is overall counterbalanced to the higher activity of the combinations.Overall,all the discussed immune-based combinations were ultimately approved by different regulatory authorities,and are indeed included in the most important international guidelines.Waiting for longer follow-ups and more mature trial data,as well as for real-world experiences,in the absence of validated biomarkers,our 1st line treatment choice cannot but rely on methodologically incorrect treatment comparisons,personal preferences,and experience.

关 键 词：Renal cell carcinoma immune checkpoint inhibitors antiangiogenics SURVIVAL 

分 类 号：R73[医药卫生—肿瘤]